Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022
02 Mayo 2022 - 3:05PM
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical
company engaged in the commercialization and development of
innovative anti-infective agents to treat serious infections, today
announced that it will report its first quarter financial results
along with recent company highlights after the close of the U.S.
financial markets on Thursday, May 5, 2022. Nabriva’s management
will host a conference call at 4:30 p.m. ET to discuss the
financial results and recent corporate highlights.
The dial-in number for the conference call is 800-579-2543 for
domestic participants and 203-518-9708 for international
participants, with Conference ID # NBRVQ122. A live webcast of
the conference call can be accessed through the “Investors” tab on
the Nabriva Therapeutics website at www.nabriva.com. A replay will
be available on this website shortly after conclusion of the event
for 90 days.
About Nabriva Therapeutics
plc
Nabriva Therapeutics is a biopharmaceutical company engaged in
the commercialization and development of innovative anti-infective
agents to treat serious infections. Nabriva entered into an
exclusive agreement with subsidiaries of Merck & Co. Inc.,
Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO®
(tedizolid phosphate) in the United States and certain of its
territories. Nabriva Therapeutics received U.S. Food and Drug
Administration approval for XENLETA® (lefamulin injection,
lefamulin tablets), the first systemic pleuromutilin antibiotic for
community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics
is also developing CONTEPO™ (fosfomycin) for injection, a potential
first-in-class epoxide antibiotic for complicated urinary tract
infections (cUTI), including acute pyelonephritis.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Nabriva Therapeutics, including but not
limited to statements about the potential of XENLETA to be a
treatment option for CF patients with bacterial infections, the
timing of dosing, completion and availability of data from the
Phase 1 clinical trial of XENLETA, the clinical utility of XENLETA
for CABP, SIVEXTRO for ABSSSI and of CONTEPO for cUTI, the impact
of macro events on sales of SIVEXTRO and XENLETA, plans for and
timing of the review of regulatory filings for XENLETA and CONTEPO,
efforts to bring CONTEPO to market, the market opportunity for and
the potential market acceptance of XENLETA for CABP, SIVEXTRO for
ABSSSI and CONTEPO for cUTI, the development of XENLETA and CONTEPO
for additional indications, plans to pursue research and
development of other product candidates, expectations regarding the
impact of the interruptions resulting from COVID-19 on its
business, the sufficiency of Nabriva Therapeutics’ existing cash
resources and its expectations regarding anticipated revenues from
product sales and how far into the future its existing cash
resources will fund its ongoing operations and other statements
containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “likely,” “will,” “would,” “could,” “should,”
“continue,” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: the content and timing of decisions
made by the U.S. Food and Drug Administration and other regulatory
authorities, the uncertainties inherent in the initiation and
conduct of clinical trials, availability and timing of data from
clinical trials, whether results of early clinical trials or
studies in different disease indications will be indicative of the
results of ongoing or future trials, uncertainties associated with
regulatory review of clinical trials and applications for marketing
approvals, the availability or commercial potential of CONTEPO for
the treatment of cUTI, the extent of business interruptions
resulting from the infection causing the COVID-19 outbreak or
similar public health crises, the ability to retain and hire key
personnel, the availability of adequate additional financing on
acceptable terms or at all and such other important factors as are
set forth in Nabriva Therapeutics’ annual and quarterly reports and
other filings on file with the U.S. Securities and Exchange
Commission. In addition, the forward-looking statements included in
this press release represent Nabriva Therapeutics’ views as of the
date of this press release. Nabriva Therapeutics anticipates that
subsequent events and developments will cause its views to change.
However, while Nabriva Therapeutics may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Nabriva Therapeutics’ views as of any date subsequent
to the date of this press release.
CONTACT:
For Investors and MediaKim AndersonNabriva
Therapeutics plcir@nabriva.com
Nabriva Therapeutics (NASDAQ:NBRV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Nabriva Therapeutics (NASDAQ:NBRV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024